Medtronic to offer $2B in senior debt notes; Teleflex is paying a quarterly cash dividend;

@FierceMedDev: At J&J's Coridis, at least, renal denervation is continuing to advance. Press release | Follow @FierceMedDev

@MarkHFierce: I spoke to Daktari Diagnostics' CEO about the company's Series D fundraising efforts. Story via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

@GalenMoore: Sham surgeries: Medtech's placebos? Or a waste of money at patients' risk? via Forbes | Follow @GalenMoore

> Medtronic ($MDT) will offer $2 billion in senior debt notes for working capital and debt refinancing. Story

> Paradigm Spine has raised $75 million in secured debt financing to refinance existing debt and expand commercial operations for its spinal implant devices. Item

> Samsung will establish a research lab at the University of California, San Francisco at which to develop and test new mobile health technology. Item

> Tissue Fusion plans to commercialize a new laser device based on technology developed at the University of Colorado that closes wounds during surgery. Story

> Teleflex ($TFX), which makes critical care and surgical medical devices, is paying a quarterly cash dividend of 34 cents per share. Item

Biotech News

@FierceBiotech: Belgian UCB gets ready for CEO change plus more career changes in biopharma in this week's Chutes & Ladders. | Follow @FierceBiotech

@JohnCFierce: Merck KGaA has the firepower to pull off a big buyout, but will it? Story | Follow @JohnCFierce

@DamianFierce: Ariad's new board member is an activist investor with a history of pushing companies to sell. More | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story from FierceBiotech Research | Follow @EmilyMFierce

> EU breathes hope into GlaxoSmithKline's latest respiratory contender. Article

> Isis gears up for Phase III with Biogen-partnered antisense drug. News

Pharma News

@FiercePharma: ICYMI: WHO reports success in distributing vaccines at ambient temperatures. Story via FierceVaccines. | Follow @FiercePharma

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Story | Follow @EricPFierce

@CarlyHFierce: Tops on the old FP site yesterday: Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit. Story | Follow @CarlyHFierce

> FDA moves toward major overhaul of the way it approves OTC meds. Article

> EU Anoro nod lets GSK breathe deeper as Advair faces generic onslaught. Story

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.